1 2 3 4 5 6 7 8 9 10 11
далее D. W., Mclnnes I. B. The antiinflammatory effects of statins. N. Engl. J. Med. 2001; 345: 1209-1211. 35. Hernandez-Presa M. A., Martin-Ventura J. L., Ortega M. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002; 160: 49—58. 36. Ridker P. M., Cushman M., Stampfer M. J. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 1997; 336: 973-979. 37. Halkin A., Keren G. Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am. J. Med. 2002; 112: 126—134. 38. Peason T. Markers of Inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the centers for disease control and prevention. Circulation 2003; 107: 499—511. 39. Pearson T. A., Mensah G. A., Hong Y., Smith S. C. CDC/ AHA Workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice. Circulation 2004; 110 (25): e543-e544. 40. Smith E. В., Thompson W. D. Fibrin as a factor in atherogenesis. Thromb. Res. 1994; 73: 1—19. 41. Smith E. В., Crosbie L. Does lipoprotein compete with plasminogen in human atherosclerotic lesions and thrombi? Atherosclerosis 1991; 89: 127-136. 42. Yarnell J. W., Baker I. A., Sweetnam P. M. Fibrinogen, viscosity and white blood cell counts are major risk factor for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991; 83: 836—844. 43. Heinrich J., Balleisen L., Schulte H. Fibrinogen and factor Vll in the prediction of coronary risk. Results from the PRO-CAM study in healthy men. Arterioscler. Thromb. 1994; 14: 54—59. 44. Ernst E., Resch К. L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann. Intern. Med. 1993; 118: 956-963. 45. Montalescot G., Ankri A., Vicaut E. Fibrinogen after coronary • angioplasty as a risk factor for restenosis. Circulation 1995; 92; 31-38. 46. Rosengren A., Wilhelmsen L. Fibrinogen, coronary heart disease and mortality from all causes in smokers and nonsmokers. The Study of Men Born in 1933. J. Intern. Med. 1996; 230: 499507. 47. Toss H., Lindahl В., Siegbahn A. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997; 96: 4204-4210. 48. Behar S. Lowering fibrinogen levels: clinical update. BIP Study Group. Beza-fibrate Infarction Prevention. Blood Coagul. Fibrinolys. 1999; 63: 1041-1043. 49. Brunner E., Smith G. D., Marmot M. Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen. Lancet 1996; 347: 1008—1013. 50. Muldoon M. F., Herbert Т. В., Patterson S. M. Effects of acute psychological stress on serum lipid levels, h далее ...